An Open-Label Dose-Exploration Cohort Study Evaluating the Efficacy and Safety of Voclosporin in Achieving Complete or Partial Remission of Proteinuria in Subjects With Focal Segmental Glomerulosclerosis

Trial Profile

An Open-Label Dose-Exploration Cohort Study Evaluating the Efficacy and Safety of Voclosporin in Achieving Complete or Partial Remission of Proteinuria in Subjects With Focal Segmental Glomerulosclerosis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Aug 2018

At a glance

  • Drugs Voclosporin (Primary)
  • Indications Focal segmental glomerulosclerosis; Nephrotic syndrome
  • Focus Proof of concept; Therapeutic Use
  • Acronyms AURONA™
  • Sponsors Aurinia Pharmaceuticals
  • Most Recent Events

    • 25 Jun 2018 Status changed from planning to recruiting, according to an Aurinia Pharmaceuticals media release.
    • 10 May 2018 According to an Aurinia Pharmaceuticals media release, this trial is expected to initiate in June 2018.
    • 15 Mar 2018 According to an Aurinia Pharmaceuticals media release, a pre-IND meeting was completed in February 2018 and this trial will begin Q2 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top